Literature DB >> 10910712

Plasmodium falciparum: cloned and expressed CIDR domains of PfEMP1 bind to chondroitin sulfate A.

R Degen1, N Weiss, H P Beck.   

Abstract

Adherence of erythrocytes infected with mature asexual Plasmodium falciparum parasites (iRBC) to microvascular endothelial cells contributes to the pathology of P. falciparum malaria. It has been shown that the variant P. falciparum erythrocyte membrane protein 1 (PfEMP1) confers adhesion to a wide range of cell surface receptors. Previously, the cysteine-rich interdomain region (CIDR) of PfEMP1 has been identified as binding site to CD36. We provide evidence that the same region can also mediate binding to chondroitin sulfate A (CSA). CIDR domains of two different parasite strains were expressed in Escherichia coli as a 6xHis-tagged protein. Purified recombinant protein bound to Chinese hamster ovary (CHO) cells which naturally express chondroitin sulfate A. Treatment of wild-type CHO cells with chondroitinase ABC reduced binding up to 94.4%. Competitive binding using soluble CSA inhibited binding to CHO cells by up to 100% at 2 mg/ml and by 62.4% at 0.5 mg/ml, whereas 1 mg/ml heparan sulfate had only a little effect (18.1%). In contrast, a recombinant 6xHis-tagged DBL1 domain showed no binding to wild-type CHO cells. Such an approach of analyzing various domains of PfEMP1 as recombinant proteins may elucidate their functions and may lead to novel anti-adherence therapeutics, especially for maternal malaria infections. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10910712     DOI: 10.1006/expr.2000.4512

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  7 in total

1.  Adhesion specificities of Plasmodium falciparum-infected erythrocytes involved in the pathogenesis of pregnancy-associated malaria.

Authors:  Lars Hviid
Journal:  Am J Pathol       Date:  2007-06       Impact factor: 4.307

2.  Rapid acquisition of isolate-specific antibodies to chondroitin sulfate A-adherent plasmodium falciparum isolates in Ghanaian primigravidae.

Authors:  Sharon E Cox; Trine Staalsoe; Paul Arthur; Judith N Bulmer; Lars Hviid; Kojo Yeboah-Antwi; Betty R Kirkwood; Eleanor M Riley
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

3.  A single member of the Plasmodium falciparum var multigene family determines cytoadhesion to the placental receptor chondroitin sulphate A.

Authors:  Nicola K Viebig; Benoit Gamain; Christine Scheidig; Catherine Lépolard; Jude Przyborski; Michael Lanzer; Jürg Gysin; Artur Scherf
Journal:  EMBO Rep       Date:  2005-08       Impact factor: 8.807

4.  Nonspecific immunoglobulin M binding and chondroitin sulfate A binding are linked phenotypes of Plasmodium falciparum isolates implicated in malaria during pregnancy.

Authors:  Alison M Creasey; Trine Staalsoe; Ahmed Raza; David E Arnot; J Alexandra Rowe
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

5.  Lack of gender-specific antibody recognition of products from domains of a var gene implicated in pregnancy-associated Plasmodium falciparum malaria.

Authors:  Anja T R Jensen; Hanne D Zornig; Caecilie Buhmann; Ali Salanti; Kwadwo A Koram; Eleanor M Riley; Thor G Theander; Lars Hviid; Trine Staalsoe
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

6.  Specific receptor usage in Plasmodium falciparum cytoadherence is associated with disease outcome.

Authors:  Lucy B Ochola; Bethsheba R Siddondo; Harold Ocholla; Siana Nkya; Eva N Kimani; Thomas N Williams; Johnstone O Makale; Anne Liljander; Britta C Urban; Pete C Bull; Tadge Szestak; Kevin Marsh; Alister G Craig
Journal:  PLoS One       Date:  2011-03-03       Impact factor: 3.240

7.  Evidence for the involvement of VAR2CSA in pregnancy-associated malaria.

Authors:  Ali Salanti; Madeleine Dahlbäck; Louise Turner; Morten A Nielsen; Lea Barfod; Pamela Magistrado; Anja T R Jensen; Thomas Lavstsen; Michael F Ofori; Kevin Marsh; Lars Hviid; Thor G Theander
Journal:  J Exp Med       Date:  2004-11-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.